ORIGINAL ARTICLE
Year : 2015  |  Volume : 14  |  Issue : 3  |  Page : 187-195

Design, synthesis, and in-vitro antiproliferative effect of some novel 1,3,4-oxadiazole derivatives bearing benzimidazole nucleus


1 Department of Biochemistry, Sumandeep Vidyapeeth University, Vadodara, Gujarat, India
2 Department of Drug Discovery R&D, Century Pharmaceuticals Ltd, Vadodara, Gujarat, India

Correspondence Address:
Ujjwal Sahoo
PhD, Department of Biochemistry, Sumandeep Vidyapeeth University, Vadodara - 391 760, Gujarat
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1687-4315.172865

Rights and Permissions

Background and objectives Development of a novel compound containing a heterocyclic nucleus as an anticancer therapeutic agent is the most important focal point in medicinal chemistry. Programmed cell death or apoptosis is a fundamental phenomenon and plays a central role in immune regulation, embryogenesis, and general tissue homeostasis. Therefore, identification of novel potent, selective, and less toxic anticancer agents is one of the most crucial concerns. Materials and methods A series of 4-{1-[(4-acetyl-5-(substituted)-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl]-5-nitro-1H-benzimidazol-2-yl}benzonitrile 6 (I-IV) and novel 4-{5-substituted-1-[(4,5-disubstituted)-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl]-5-nitro-1H-benzimidazol-2-yl}benzonitrile 7 (V-XXXIII) derivatives were synthesized. Results and conclusion Nine of them were selected by the Department of Biotechnology Drug Discovery R&D, Century Pharmaceuticals Ltd, for evaluation of their in-vitro anticancer activity. Three of the investigated compounds, 7.X, 7.XIX , and 7.XXIV , displayed in-vitro anticancer activity in the primary assay. These compounds were selected for a full anticancer screening against a three-cell panel MTT assay, and they showed a nonselective broad spectrum antiproliferative activity against L929, HCT15, and Hep2 cancer cell lines. Compound 7.XIX showed antiproliferative activity, which can be comparable to that of 5-fluorouracil, methotrexate, and daunorubicin, and this compound has been identified as a promising lead compound.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed755    
    Printed24    
    Emailed0    
    PDF Downloaded123    
    Comments [Add]    

Recommend this journal